Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1WZYB | ISIN: US3723032062 | Ticker-Symbol: GE91
Siehe auch GENMAB A/S
Tradegate
31.03.25
09:30 Uhr
18,200 Euro
-0,200
-1,09 %
1-Jahres-Chart
GENMAB A/S ADR Chart 1 Jahr
5-Tage-Chart
GENMAB A/S ADR 5-Tage-Chart
RealtimeGeldBriefZeit
18,10018,20021:55

Aktuelle News zur GENMAB A/S ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:26GENMAB A/S - 6-K, Report of foreign issuer4
17:24Genmab A/S: TIVDAK (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer179TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global...
► Artikel lesen
14:24Genmab A/S: Transactions in connection with share buy-back program5
FrGenmab's Tivdak approved in Japan for advanced cervical cancer5
DoJapanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer3
DoGenmab and BridgeBio Pharma announce Japan approval for their treatments5
GENMAB A/S ADR Aktie jetzt für 0€ handeln
DoGenmab Announces Approval Of TIVDAK In Japan3
DoGenmab A/S: TIVDAK (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy294TIVDAK is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in Japan Approval is based on results from the global Phase 3...
► Artikel lesen
DiGenmab startet Aktienrückkaufprogramm im Wert von 610 Millionen US-Dollar5
DiGenmab launches $610 million share buyback program6
DiGenmab A/S: Genmab Announces Initiation of Share Buy-Back Program2
DiAbbVie sues Genmab, claiming trade secrets theft49
24.03.AbbVie takes Genmab to court, accusing partner of being 'willfully blind' to ADC trade secret theft2
22.03.Genmab To Vigorously Defend Against AbbVie's Trade Secret Misappropriation Claims824COPENHAGEN (dpa-AFX) - Genmab A/S (GMAB) announced that it will vigorously defend itself against allegations of trade secret misappropriation brought by AbbVie Inc. (ABBV).AbbVie has filed a...
► Artikel lesen
22.03.Genmab A/S: Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.603Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously...
► Artikel lesen
20.03.GENMAB A/S - 6-K, Report of foreign issuer6
17.03.Genmab A/S: Investigational Rinatabart Sesutecan (Rina-S) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer264Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed...
► Artikel lesen
17.03.Genmab: Investigational Rinatabart Sesutecan (Rina-S) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer288Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate (ORR) of 55.6% and median...
► Artikel lesen
14.03.William Blair Forecasts Genmab A/S FY2029 Earnings41
12.03.Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons7
Seite:  Weiter >>
128 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1